» Articles » PMID: 26376897

Molecular Studies of Lupus Nephritis Kidneys

Overview
Journal Immunol Res
Date 2015 Sep 18
PMID 26376897
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Lupus nephritis is a devastating complication of systemic lupus erythematosus (SLE) for which current therapies are insufficiently effective. Histologic evaluation of renal biopsies is a poor predictor of therapeutic response or outcome. Integrated immunologic, genomic and proteomic approaches may yield new insights into disease pathogenesis and thereby improve therapeutic strategies for lupus nephritis. Given the lack of sequential biopsies from humans, it also remains essential to study informative animal models of disease. Cross-species analyses can identify cells or pathways that are relevant to human disease and can be further studied in mouse models. Using a systems biology approach in which we compare molecular data from kidneys of three different mouse models of lupus nephritis with data from human lupus biopsies, we have found that inflammatory events escalate rapidly around the time of proteinuria onset. This is followed by hypoxia and metabolic stress, and by tubular and endothelial dysfunction. The failure of complete reversal of these abnormalities may increase the sensitivity of the kidney to further insult. We further found that renal macrophages and dendritic cells are key players in lupus nephritis both in mouse models and humans and that macrophages display a hybrid molecular profile that reflects incomplete resolution of inflammation and excessive tissue remodeling. Finally, our studies have suggested several new biomarkers for disease stage that can now be tested longitudinally in human SLE patients.

Citing Articles

Mechanism of curcumin in the prevention and treatment of oral submucosal fibrosis and progress in clinical application research.

She R, Xu P BDJ Open. 2024; 10(1):82.

PMID: 39455570 PMC: 11512022. DOI: 10.1038/s41405-024-00268-7.


EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus.

Gallo P, Chain R, Xu J, Whiteman L, Palladino A, Caricchio R Int Immunopharmacol. 2024; 140:112692.

PMID: 39079344 PMC: 11456265. DOI: 10.1016/j.intimp.2024.112692.


Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses.

Muchamuel T, Fan R, Anderl J, Bomba D, Johnson H, Lowe E Front Immunol. 2023; 14:1043680.

PMID: 36969170 PMC: 10036830. DOI: 10.3389/fimmu.2023.1043680.


Curcumin attenuates autoimmunity and renal injury in an experimental model of systemic lupus erythematosus.

Dent E, Taylor E, Turbeville H, Ryan M Physiol Rep. 2020; 8(13):e14501.

PMID: 32652896 PMC: 7354090. DOI: 10.14814/phy2.14501.


Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis.

Yang Y, Luo R, Cheng Y, Liu T, Dai W, Li Y BMC Nephrol. 2020; 21(1):122.

PMID: 32252660 PMC: 7137487. DOI: 10.1186/s12882-020-01782-0.


References
1.
Lin S, Castano A, Nowlin B, Lupher Jr M, Duffield J . Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol. 2009; 183(10):6733-43. DOI: 10.4049/jimmunol.0901473. View

2.
Mok C, Ying K, Tang S, Leung C, Lee K, Ng W . Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004; 50(8):2559-68. DOI: 10.1002/art.20364. View

3.
Bethunaickan R, Berthier C, Zhang W, Eksi R, Li H, Guan Y . Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice. Arthritis Rheumatol. 2014; 66(8):2246-2258. PMC: 4554534. DOI: 10.1002/art.38679. View

4.
Kono D, Theofilopoulos A . Genetics of systemic autoimmunity in mouse models of lupus. Int Rev Immunol. 2000; 19(4-5):367-87. DOI: 10.3109/08830180009055504. View

5.
Li L, Huang L, Sung S, Vergis A, Rosin D, Rose Jr C . The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int. 2008; 74(12):1526-37. PMC: 2652647. DOI: 10.1038/ki.2008.500. View